The Safety and Efficacy Evaluation of Echocardiography-guided Percutaneous Radiofrequency Ablation for Cardiac Tumors: a Single-arm, Prospective, Single-center Clinical Study

Prior treatment

• Previously documented persistent ventricular tachycardia or ventricular fibrillation, supraventricular tachycardia with hemodynamic disturbance, cardiac arrest, and high atrioventricular block;
• Previous history of tumor or thromboembolism exfoliating organ embolism;
• Active infections should be treated with antibiotics;

Other illness

• Combined with other heart diseases requiring surgical treatment;
• Bleeding constitution and coagulation disorders, or anticoagulation, antiplatelet therapy contraindications;
• The disease will cause difficulties in the evaluation of treatment, such as mental illness, metabolic disease, etc.;
• Severe liver, kidney, lung, brain and other major organ failure;
• Other diseases deemed unsuitable for inclusion by the researchers;

Other

• Patients who are pregnant, breastfeeding or planning to become pregnant during the clinical study;
• Patients who cannot tolerate general anesthesia;
• There are no patients who are suitable for the injection path of Liwen operation;
• The researcher judged that the patients' dependence was poor and could not complete the study.

• Hemodynamic changes caused by cardiac tumors or patients with obvious clinical symptoms such as chest tightness, shortness of breath, palpitations, etc., or the risk of embolization of intracardial tumors;
• Patients who cannot be completely excised by surgery, cannot tolerate surgery or refuse surgery;
• The patient was informed of the nature of the clinical study and agreed to participate in all the requirements of the clinical study, signed the informed consent, and agreed to complete the follow-up and follow-up examination required.